Accessibility Menu
VivoSim Labs logo

VivoSim Labs

(NASDAQ) VIVS

Current Price$0.58
Market Cap$2.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)-100%
5 Year-99%
1 Year-66%
1 Month-48%
VivoSim Labs last closing stock price
MetricPriceDate
Last closeUSD 0.612026-07-16
VivoSim Labs stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-23.41%USD 0.802026-07-09
1 month-47.56%USD 1.172026-06-16
3 month-61.89%USD 1.612026-04-17
Year to date-66.1%USD 1.812025-12-31
1 year-66.1%USD 1.812025-07-16
3 year-96.99%USD 20.402023-07-17
5 year-99.33%USD 91.922021-07-16
Since inception-99.85%USD 396.002012-02-14

VivoSim Labs Financials at a Glance

Market Cap

$2.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$131.00K

Net Income (TTM)

-$13.84M

EPS (TTM)

-$5.35

P/E Ratio

-0.11

Dividend

$0.00

Beta (Volatility)

0.76 (Low)

Price

$0.58

Volume

2,743,882.924

Open

$0.57

Previous Close

$0.61

Daily Range

$0.52 - $0.59

52-Week Range

$0.52 - $5.30

Estimated Earnings Date

Aug 6, 2026

VIVS News

Organovo

Why Organovo Holdings, Inc. Stock Soared 49.7% This Week

James HalleyMar 3, 2022
biotech down

Here's Why Organovo Holdings Stock Fell as Much as 28.4% Today

Maxx ChatskoJun 1, 2018
crystal-ball--chart-prediction-getty

Where Will Organovo Holdings, Inc. Be in 5 Years?

Cory RenauerDec 3, 2017
Handing money to doctor

Why Tiny Organovo Is Giving Money to Huge Biotech Amgen

Keith SpeightsAug 30, 2017
Financial report

Organovo Holdings Revenue Is Growing at a Snail's Pace Compared With Prior Quarters

Keith SpeightsAug 10, 2017
Risk - measuring

How Risky Is Organovo Holdings, Inc.?

Keith SpeightsJul 18, 2017
money falling through hands

Here's Why Organovo Holdings Inc Fell 10.5% in June

Brian FeroldiJul 10, 2017
Management watching stock tank

3 Reasons Organovo Holdings, Inc. Stock Could Fall Even More

Keith SpeightsJun 22, 2017
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About VivoSim Labs

VivoSim Labs creates 3D human tissue models for drug testing and research. Its technology helps pharmaceutical companies predict drug safety without animal testing. Hospitals and researchers use these models to study diseases and develop new treatments.

Products and Services

  • 3D Human Tissue Platform: Automated NovoGen Bioprinters create living tissues for research. Revenue currently arises from licensing related to this platform.
  • Liver and Intestinal Toxicology Services: Predicts drug safety for pharmaceutical and biotech clients.
  • Custom Research Services: Offers tailored studies on drug mechanisms and disease modeling.
  • Drug Discovery Programs: Develops new drug candidates for inflammatory bowel disease.
  • Intellectual Property Licensing: Licenses bioprinter and bioink patents to other companies.

Growth and Expansion

  • Changed name from Organovo to VivoSim Labs in April 2025 to reflect new focus.
  • Sold FXR314 drug program in March 2025 for $10 million to support service-based model.
  • Launched new toxicology services after FDA regulatory changes in April 2025.
  • Formed research collaborations with Yale School of Medicine, Knight Cancer Institute, and University of Virginia.
  • Signed non-exclusive licensing deal with BICO Group AB for bioprinter patents.

What Makes VivoSim Labs Stand Out

VivoSim Labs uses proprietary 3D bioprinting to create human tissue models that closely mimic real organs. Its technology supports non-animal drug testing, aligning with new regulatory trends. The company’s research collaborations and licensing deals extend its reach beyond direct sales.

Five Things You Need to Know

  • Revenue was $28,000 in QQ2 2026, down 6.7% from QQ2 2025.
  • Operating loss was $3 million in QQ2 2026, improved 1.0% year-over-year.
  • Cash and equivalents were $9.1 million as of June 30, 2025.
  • R&D expenses fell 29% year-over-year to $1 million in QQ2 2025.
  • Company has 14 employees and a market cap of $5.01 million as of February 2026.

Bottom Line

VivoSim Labs shifted from drug development to service-based research using advanced tissue models. The company faces ongoing losses but adapts to industry changes and regulatory trends.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

15

CEO

Keith Murphy

Website

vivosim.ai

Headquarters

San Diego, CA 92121, US

VIVS Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-8567.94%

Net Income Margin

-10567.18%

Return on Equity

-277.62%

Return on Capital

N/A

Return on Assets

-187.42%

Earnings Yield

-9.09%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.49M

Volume

2.74M

Avg. Volume

2.14M

Financials (TTM)

Gross Profit

$131.00K

Operating Income

-$11.22M

EBITDA

-$13.57M

Operating Cash Flow

-$10.83M

Capital Expenditure

$0.00

Free Cash Flow

-$10.83M

Cash & ST Invst.

$5.02M

Total Debt

$447.00K

VivoSim Labs Performance Analysis

VivoSim Labs annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31USD 370,000-75.3%
20242024-03-31USD 109,000-70.5%
20252025-03-31USD 144,00032.1%
20262026-03-31USD 131,000-9.0%
VivoSim Labs sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-30-27.5%
Q22025-09-30-24.3%
Q32025-12-31-7.1%
Q42026-03-3153.8%
VivoSim Labs annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31USD -23.7750.6%
20242024-03-31USD -19.25-19.0%
20252025-03-31USD -1.70-91.2%
20262026-03-31USD -5.35214.6%
VivoSim Labs sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-30-141.5%
Q22025-09-3010.3%
Q32025-12-31-5.7%
Q42026-03-31-20.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$40.00K

-21.6%

Gross Profit

$40.00K

-21.6%

Gross Margin

100.00%

N/A

Market Cap

$2.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$153.14K

N/A

Employees

14

N/A

Net Income

-$5.76M

-184.1%

EBITDA

-$5.67M

-181.9%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$5.02M

-55.6%

Total Debt

$447.00K

-52.5%

Accounts Receivable

$1.05M

+3386.7%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$447.00K

-14.2%

Return on Assets

-1.87%

N/A

Return on Invested Capital

-2.44%

N/A

Free Cash Flow

-$2.24M

-10.0%

Operating Cash Flow

-$2.24M

-10.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KTTAPasithea Therapeutics Corp.
$0.45-0.77%
PMCBPharmaCyte Biotech, Inc.
$0.66+0.03%
TCRTAlaunos Therapeutics, Inc.
$2.02-2.42%
RADXRadiopharm Theranostics Limited
$4.30+0.23%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$67.07-0.05%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$27.44-0.00%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$42.99+0.05%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.36-0.05%

Questions About VIVS

What is the current price of VivoSim Labs?

VivoSim Labs is trading at $0.58 per share.

What is the 52-week range for VivoSim Labs?

Over the past 52 weeks, VivoSim Labs has traded between $0.52 and $5.30.

How much debt does VivoSim Labs have?

As of the most recent reporting period, VivoSim Labs reported total debt of $565.00K.

How much cash does VivoSim Labs have on hand?

VivoSim Labs reported $5.02M in cash and cash equivalents in its most recent financial results.

What is VivoSim Labs’s dividend yield?

VivoSim Labs does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services